Order
This cause comes before the Court for consideration of Defendant AstraZeneca’s Motion to Dismiss (Doc. 19) and Defendant Parexel’s Motion to Dismiss (Doc. 18). Plaintiffs filed a consolidated response to both motions (Doc. 28), 1 and Defendant AstraZeneca subsequently filed a reply (Doc. 33). Upon careful consideration of the motions and memoranda, the Court determines that both motions are due to be GRANTED.
I. BACKGROUND
In this putative class action, various union health and welfare benefit funds 2 and an individual consumer seek redress for economic injuries they say they sustained as a result of a “nationwide, uniform marketing campaign involving fraudulent misstatements and deceptive conduct in the promotion of Seroquel,” an atypical anti-psychotic drug manufactured by Defendant AstraZeneca. Doc. 17 at 4. According to Plaintiffs, this alleged scheme was devised and carried out by Defendant AstraZeneca in alliance with Defendant Parexel, a medical marketing firm employed by AstraZeneca in 2001 to provide “publications planning, meetings support, branding strategy, marketing solutions and advocacy programs relating to Seroquel.” Id. at 46.
Plaintiffs allege that the AstraZeneca/Parexel alliance both “misrepresented the comparative safety, efficacy and superiority of Seroquel over other traditional/typieal or atypical antipsyehotics,” Id. at 4, and “illegally marketed and promoted Seroquel for unapproved or ‘off-label’ uses,” Id. at 3. This scheme was allegedly accomplished through the following mechanisms: concealment of unfavorable results of clinical trials; aggressive promotion of the drug as safe and effective for uses not approved by the FDA; substantial contributions to non-profit mental health organi *1342 zations; sponsorship of peer-selling events at which physicians were given financial incentives both to attend the event and to speak favorably about Seroquel to their peers; employment of “ghost-writers” to author seemingly-independent medical publications touting the superior safety and effectiveness of Seroquel; and distribution of marketing and promotional materials directly to physicians which concealed or misrepresented facts about the drug’s safety and effectiveness.
As a result of Defendants’ conduct, Plaintiffs claim that they were duped into paying hundreds of millions of dollars for Seroquel both to treat conditions for which the drug was not approved and where less expensive, and equally safe and effective, alternative treatments existed. Meanwhile, according to Plaintiffs, Defendant AstraZeneca saw a marked increase in demand for Seroquel; the company raked in over $4.6 billion in sales of the drag in 2007 alone. Id. at 57. Plaintiffs maintain that had they known of Defendants’ fraudulent scheme, they would have taken steps to minimize the number of doses of Seroquel they purchased by, among other things, excluding Seroquel from approved schedules or actively dissuading doctors from prescribing Seroquel to their patients. Id. at 59.
Plaintiffs have filed a consolidated complaint (Doe. 17) asserting claims under the federal Racketeer Influenced and Corrupt Organizations (“RICO”) statute and state consumer protection laws as well as common law claims for fraud, misrepresentation, civil conspiracy and unjust enrichment. Defendants now seek to dismiss the complaint in its entirety for failure to state a claim.
II. LEGAL STANDARD
In deciding a motion to dismiss, the court must accept as true all the factual allegations in the complaint, drawing all inferences derived from those facts in the light most fávorable to the plaintiff.
Brown v. Crawford County,
III. DISCUSSION
A. Counts I and II: Civil RICO Claims
In Counts I and II of the consolidated complaint, Plaintiffs seek to recover damages by way of the civil remedies provision of the federal RICO statute. 3 In general, the federal RICO statute prohibits any person from participating in a pattern of racketeering activity or from collecting an unlawful debt. See generally 18 U.S.C. § 1962. A pattern of racketeering activity is defined to encompass a wide range of acts which are indictable as *1343 crimes involving fraud, bribery, theft, embezzlement or extortion. See 18 U.S.C. § 1961(1). In this case, Plaintiffs allege that Defendants’ pattern of racketeering activity involved acts that are indictable under 18 U.S.C. §§ 1341 and 1343, relating to mail and wire fraud.
The civil remedies provision of the federal RICO statute provides that “[a]ny person injured in his business or property by reason of a violation of section 1962 of this chapter may sue therefor in any appropriate United States district court and shall recover threefold the damages he sustains and the cost of the suit, including a reasonable attorney’s fee.” 18 U.S.C. § 1964(c). Thus, the essential elements of a civil RICO claim are: (1) a violation of section 1962; (2) injury to business or property; and (3) a causal connection between the violation and the injury.
Avirgan v. Hull,
Defendants present two main arguments with regard to causation. First, Defendants maintain that Plaintiffs have failed to demonstrate any detrimental reliance on the alleged misstatements made by Defendants in furtherance of their scheme to defraud. Second, Defendants assert that even if Plaintiffs have shown detrimental reliance, they still cannot establish the requisite causal connection between Defendants’ RICO violation and Plaintiffs’ injuries.
The most recent United States Supreme Court authority on pleading and proving detrimental reliance in relation to a civil RICO claim is
Bridge v. Phoenix Bond & Indem. Co.,
— U.S. -,
As was established by the United States Supreme Court in
Holmes v. Sec. Investor Prat. Corp.,
First, the less direct an injury is, the more difficult it becomes to ascertain the amount of a plaintiffs damages attributable to the violation, as distinct from other, independent, factors. Second, quite apart from problems of proving factual causation, recognizing claims of the indirectly injured would force courts to adopt complicated rules apportioning damages among plaintiffs removed at different levels of injury from the violative acts, to obviate the risk of multiple recoveries. And, finally, the need to grapple with these problems is simply unjustified by the general interest in deterring injurious conduct, since directly injured victims can generally be counted on to vindicate the law as private attorneys general, without any of the problems attendant upon suits by plaintiffs injured more remotely.
Holmes,
In view of the “direct relation” standard enunciated by the Holmes Court and the various policies supporting that standard, the Court concludes that Plaintiffs have not established that their injuries were proximately caused by Defendants’ alleged scheme to defraud. Indeed, allowing Plaintiffs to move forward on their civil RICO claims would present precisely the types of problems the Holmes Court sought to avoid.
In relation to the first
Holmes
factor, this case raises serious concerns regarding the ascertainment of damages caused by Defendants’ alleged fraudulent conduct, as opposed to damages caused by other, independent, factors. The key independent factor in this case stems from the fact that consumers may only obtain Seroquel through a prescription from a physician. Presumably, these physicians use their independent medical judgment to decide whether Seroquel is the best treatment for a given patient. This independent judgment can be influenced by a number of things, only one of which may be representations by a manufacturer as to a particular drug’s relative safety and efficacy, Thus, in the context of this case, establishing that Plaintiffs’ injuries were caused by Defendants’ misconduct would require an inquiry into the specifics of each doctor-patient relationship implicated by the lawsuit, In other words, each physician who prescribed Seroquel to an individual consumer or health and welfare fund member would have to be questioned as to whether his or her independent medical judgment was influenced by Defendants’ misrepresentations, and to what extent. Furthermore, as Defendant AstraZeneca points out in its motion, this individualized inquiry would likely have to be conducted with regard to each consumer purchase transaction or third-party reimbursement payment made over the last approximately ten years, This is precisely the type of “intricate, uncertain inquir[y]” the
Holmes
Court sought to prevent.
Anza,
In relation to the second and third
Holmes
factors, Defendants have not plausibly identified any victims of Defendants’ alleged fraudulent marketing scheme other than Plaintiffs. Thus, admittedly, this case likely would not require the adoption of complicated apportionment rules in order to fairly compensate victims at various
*1345
levels of injury, nor does it implicate concerns about whether more direct victims can be relied upon to “vindicate the law as private attorneys’ general,”
Holmes,
B. Counts III-VTI: State and Common Law Claims
As the class certification issue has not yet been reached in this case, the Court has considered the state and common law claims asserted by Plaintiffs in the context of only the three states in which the representative plaintiffs claim to reside, i.e., New Jersey, Pennsylvania, and Tennessee,
1. Counts III, VI and VII: State Consumer Protection Statutes; Common Law Fraud and Negligent Misrepresentation
In Count III, Plaintiffs allege that Defendants’ alleged scheme to defraud violates the consumer protection statutes of all but four states. In order to prevail on a consumer protection claim in New Jersey, Pennsylvania, and Tennessee, a causal nexus between the actionable conduct and the injury sustained must be shown.
Weinberg v. Sun Co., Inc.,
The common law fraud and negligent misrepresentation claims alleged by Plaintiffs in Counts VI and VII likewise fail for lack of causation.
See McCabe v. Ernst & Young, LLP,
2. Count V: Civil Conspiracy
Under Pennsylvania, New Jersey and Tennessee common law, a civil conspiracy claim must be supported by an actionable underlying tort.
Levy v. Franks,
3. Count IV: Unjust Enrichment
Finally, the Court finds the Third Circuit Court of Appeals’ decision in
Steamfitters Local Union No. 120 Welfare Fund v. Philip Morris, Inc.,
IV. CONCLUSION
Based on the foregoing discussion, it is ORDERED as follows:
1. Defendant Parexel’s Motion to Dismiss (Doc. 18) is GRANTED.
2. Defendant AstraZeneca’s Motion to Dismiss (Doc. 19) is GRANTED.
3. A1 of Plaintiffs’ claims are hereby DISMISSED as to all Defendants.
4. Ml other pending motions are DENIED as moot.
5.The Clerk is directed to CLOSE the case.
Notes
. Plaintiffs simultaneously filed a RICO Case Statement under seal. Magistrate Judge Baker denied the motion to file under seal, finding that the Case Statement was not necessary to the determination of the Motions to Dismiss. See Doc. 41.
. These funds provide health and medical benefits to union members. In relation to prescription drugs, the funds cover all or a portion of their members' prescription drug costs either through direct payment or subsequent reimbursement.
. Plaintiffs allege in Count I that Defendants violated 18 U.S.C. § 1962(c), which prohibits any person “employed by or associated with any enterprise engaged in, or the activities of which affect, interstate or foreign commerce” from participating in the conduct of the enterprise's affairs "through a pattern of racketeering activity or collection of unlawful debt.” Plaintiffs allege in Count II that Defendants violated 18 U.S.C. § 1962(d), which prohibits any person from conspiring to violate any of the other § 1962 provisions.
.' In light of the Court’s other rulings herein, the Court need not reach the issue of whether these allegations ■ are sufficiently pled under Fed.R.CivJP. 9(b).
. The Court recognizes that Parexel and AstraZeneca stand on unequal footing with respect to the extent of their participation in the alleged RICO conspiracy, as well as the degree of accountability for Plaintiffs’ alleged harm; however, the Court's ruling on causation renders this distinction inconsequential.
. The Court additionally notes, and the parties do not dispute, that class actions are prohibited under the Tennessee Consumer Protection Act.
Walker v. Sunrise Pontiac-GMC Truck, Inc.,
. Steamfitters was one of several cases filed in various state and federal courts by union health and welfare funds seeking to hold tobacco companies responsible for the additional health care costs incurred by smokers. The union funds asserted claims similar to those asserted by Plaintiffs in this case, e.g., federal RICO' claims and state law claims for misrepresentation, negligence and unjust enrichment. The Third Circuit ultimately affirmed the district court’s dismissal of the *1347 claims for failure to establish proximate cause.
